From its discovery and Nobel recognition, olefin metathesis has evolved into a cornerstone of modern organometallic synthesis. It has become a practical and increasingly indispensable tool – enabling transformations that are not only elegant, but efficient, scalable, and sustainable. From pharmaceutical and fragrance chemistry to bio-based intermediates and high-performance polymers, its impact spans the full spectrum of industrial chemistry.
At the forefront of this evolution is Apeiron Synthesis, an EU-based company dedicated entirely to the advancement of olefin metathesis catalysts and processes. Combining deep R&D capabilities with industrial know-how, Apeiron is helping global partners turn breakthrough ideas into commercial advantage.
The fundamentals and why they matter now
At its core, olefin metathesis is a single, versatile reaction that enables the breaking and reforming of carbon–carbon double bonds in new arrangements. Depending on the substrates and reaction conditions, it can proceed via different pathways, including:
- Cross Metathesis (CM)
- Ring-Closing Metathesis (RCM)
- Ring-Opening Metathesis (ROM)
- Ring-Opening Metathesis Polymerization (ROMP)
- Acyclic Diene Metathesis (ADMET)
What makes this reaction uniquely powerful is its combination of:
- Functional group tolerance
- High atom economy
- Compatibility with green solvents
- Versatility across molecular scaffolds
As process chemists increasingly aim for ecologically friendlier, shorter, and cleaner routes to complex molecules – and as industry demands greener and more selective alternatives – olefin metathesis offers a compelling solution.
Apeiron’s approach: from scientific discovery to industrial delivery
Apeiron Synthesis is a global leader dedicated exclusively to olefin metathesis technology. The company develops and manufactures a comprehensive portfolio of ruthenium-based catalysts, delivering innovative solutions for advanced chemical transformations across industries.
Apeiron stands out with exclusive access to licensed IP and a proprietary portfolio of cutting-edge ligands, from CAAC to advanced NHC variants, as well as its capacity to engineer catalysts suited to industrial processes — whether by adjusting solubility, enhancing robustness under less-than-ideal conditions, or enabling low-metal-residue profiles, a critical concern in pharmaceutical manufacturing.
Catalysts, including UltraCat, UltraNitroCat, and nitro-Grela variants, have demonstrated impressive turnover numbers (TON), high reactivity under mild conditions, and strong performance in both batch processes and demanding industrial settings. Apeiron has also validated their performance across high-impact reactions, including:
- Cross Metathesis (CM) to access key intermediates for GLP-1 analogue synthesis
- Ethenolysis of FAMEs to produce 9-DAME and 1-decene
- Production of macrocyclic musks via mRCM (e.g., exaltolide)
Catalyst loading as low as 2-10 ppm with TONs exceeding 1 million has been recorded in select applications.
Olefin Metathesis and the future of responsible synthesis
Olefin metathesis chemistry (https://apeiron-synthesis.com/the-science/technology) plays a key role in driving the sustainable transformation of the chemical industry. Whether through the use of renewable feedstocks, the shortening of synthetic routes, or improved process efficiency, its contribution supports both economic imperatives and regulatory frameworks — all in line with the core principles of green chemistry.
As the field moves forward, the demand for tailored, tested, and robust industrial-grade catalysts will only grow. With its singular focus, strong science-based approach, and flexible manufacturing, Apeiron Synthesis is positioned to lead this transformation — not through marketing promises, but through proven chemistry.
